IRIS
AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.583
AS - Asia 4.595
EU - Europa 2.045
SA - Sud America 1.308
AF - Africa 356
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 8
Totale 19.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.391
SG - Singapore 2.881
BR - Brasile 1.131
CN - Cina 894
FI - Finlandia 441
IE - Irlanda 315
NG - Nigeria 272
IT - Italia 243
DE - Germania 230
VN - Vietnam 197
HK - Hong Kong 183
FR - Francia 163
GB - Regno Unito 129
CA - Canada 128
NL - Olanda 128
SE - Svezia 106
IN - India 85
AR - Argentina 76
RU - Federazione Russa 71
TR - Turchia 66
IL - Israele 48
BE - Belgio 43
BD - Bangladesh 41
MX - Messico 37
UA - Ucraina 28
PL - Polonia 27
EC - Ecuador 26
EG - Egitto 25
ID - Indonesia 25
IQ - Iraq 22
ES - Italia 21
JP - Giappone 20
MK - Macedonia 20
CO - Colombia 19
IR - Iran 19
ZA - Sudafrica 19
UZ - Uzbekistan 18
VE - Venezuela 16
PK - Pakistan 14
PY - Paraguay 14
CZ - Repubblica Ceca 12
KE - Kenya 11
AU - Australia 10
PE - Perù 10
KR - Corea 9
MA - Marocco 9
PH - Filippine 9
RO - Romania 9
AT - Austria 8
JO - Giordania 8
AL - Albania 7
AZ - Azerbaigian 7
A2 - ???statistics.table.value.countryCode.A2??? 6
CH - Svizzera 6
CL - Cile 6
DZ - Algeria 6
GR - Grecia 6
LT - Lituania 6
NP - Nepal 6
SA - Arabia Saudita 6
TN - Tunisia 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
JM - Giamaica 5
KZ - Kazakistan 5
OM - Oman 5
BG - Bulgaria 4
PA - Panama 4
RS - Serbia 4
TW - Taiwan 4
DO - Repubblica Dominicana 3
ET - Etiopia 3
HN - Honduras 3
LV - Lettonia 3
MD - Moldavia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BB - Barbados 2
BS - Bahamas 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
MY - Malesia 2
NI - Nicaragua 2
PT - Portogallo 2
SR - Suriname 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
GD - Grenada 1
Totale 19.894
Salva come PNG Salva come JPEG
Città #
Chandler 1.920
Wilmington 1.647
Singapore 950
The Dalles 692
San Mateo 689
Dallas 542
Ann Arbor 530
Shanghai 522
Ashburn 445
Helsinki 437
Boardman 379
New York 335
Dublin 313
Leawood 310
Lawrence 288
Princeton 288
Benin City 271
Beijing 227
Hong Kong 172
Paris 153
Woodbridge 136
Fairfield 132
Amsterdam 108
São Paulo 101
Toronto 93
Milan 91
Seattle 73
Ho Chi Minh City 70
London 63
Los Angeles 59
Columbus 53
Council Bluffs 51
San Diego 49
Hanoi 48
Santa Clara 44
Brussels 42
Kocaeli 39
Rio de Janeiro 38
Norwalk 33
Moscow 29
Phoenix 28
Falls Church 27
Curitiba 24
Pune 24
Belo Horizonte 23
Warsaw 22
Falkenstein 20
Naples 20
Brooklyn 19
Brasília 18
Frankfurt am Main 18
Houston 18
Porto Alegre 17
Tokyo 16
Boston 15
Cambridge 15
Campinas 15
Monmouth Junction 15
Rome 15
San Francisco 15
Stockholm 14
Munich 13
Salvador 13
Tashkent 13
Atlanta 12
Fortaleza 12
Mexico City 12
Orem 12
Asyut 11
Des Moines 11
Montreal 11
Recife 11
Redmond 11
Redwood City 11
Andover 10
Clearwater 10
São José dos Campos 10
Baghdad 9
Betim 9
Brno 9
Chennai 9
Denver 9
Nairobi 9
Poplar 9
Seoul 9
Skopje 9
Amman 8
Assago 8
Bauru 8
Buenos Aires 8
Chicago 8
Guarulhos 8
Las Vegas 8
Manchester 8
Reston 8
Ribeirão Preto 8
Sorocaba 8
Charlotte 7
Da Nang 7
Dhaka 7
Totale 13.233
Salva come PNG Salva come JPEG
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 182
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 129
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 120
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 116
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 113
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 109
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? 104
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 104
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 101
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 101
A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019 99
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 95
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 95
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 95
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 94
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 94
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 93
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 92
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 92
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 91
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 90
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 90
From current status to optimization of HCV treatment: Recommendations from an expert panel 89
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 88
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 88
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 88
Real life experiences in HCV management in 2018 88
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 87
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 86
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 86
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 85
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 85
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 84
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 83
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 83
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy 83
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 82
EASL Recommendations on Treatment of Hepatitis C 2014 82
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 82
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 82
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 81
High mortality in COVID-19 patients with mild respiratory disease 81
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients 81
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 80
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 80
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 80
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 79
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 79
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 79
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 79
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 78
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 78
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 78
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 78
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 77
Daclatasvir for the treatment of chronic hepatitis C 77
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? 77
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 76
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 76
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 76
Are We Ready to Discontinue Hepatitis B Immunoglobulins to Prevent Hepatitis B and D Recurrence in Liver Transplant Recipients? 76
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 75
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 75
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 75
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 75
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 75
Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization 75
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 74
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 74
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 73
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 73
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 73
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 73
Prevalence and Clinical Impact of Hepatitis E Virus in Immunosuppressed Patient after Liver Transplantation 73
Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes 73
Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients 73
Mapping the human genetic architecture of COVID-19 73
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 72
Chronic hepatitis C: standard of care and perspective 72
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 71
Hepatorenal Syndrome and Novel Advances in its Management 71
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 71
Role of liver biopsy in hepatocellular carcinoma 71
Safety of vedolizumab in liver transplant recipients: A systematic review 71
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 70
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1 70
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 70
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 70
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 69
Treatment of chronic hepatitis C: can complexity pave the way towards elimination? 69
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 69
Hepatitis C treatment in patients with kidney disease 69
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 69
An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study 68
Estimating HCV disease burden - volume 3 (editorial) 68
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment 68
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 68
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 68
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 68
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 68
Totale 8.258
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.969 0 0 0 0 0 964 481 213 528 399 13 371
2021/20221.691 79 18 59 359 20 21 77 221 121 197 405 114
2022/20234.749 675 211 459 563 430 409 7 418 877 362 273 65
2023/20242.682 184 263 549 130 103 422 149 153 38 46 250 395
2024/20253.997 118 102 51 88 96 417 286 500 551 906 459 423
2025/20263.951 1.484 628 640 876 225 98 0 0 0 0 0 0
Totale 20.153